Analysis of 19,289 FAERS reports found oral semaglutide had slightly more GI side effects (30.2% vs 27.8%), while injectable semaglutide showed signals for hemorrhagic diarrhea, hepatic pain, and pancreatic failure.
19,289 adverse eventsanalyzed from the FDA database comparing oral and injectable semaglutide safety profiles over 5 years
What the researchers found
GI disorders accounted for 30.19% of oral and 27.76% of subcutaneous semaglutide adverse events. Novel signals included pancreatic failure (ROR 36.34) for injectable and Dupuytren's contracture (ROR 46.85) for oral semaglutide.
Why it matters
With millions of patients choosing between oral and injectable semaglutide, understanding the different side effect profiles helps inform that choice. Identifying new safety signals in such a widely used drug is critical for patient safety monitoring.
The numbers in context
Analysis covered FAERS database reports and social media data comparing oral and subcutaneous semaglutide adverse event patterns.
How the study worked
Pharmacovigilance analysis of 19,289 semaglutide adverse events from FDA FAERS database (Q1 2018-Q2 2023) and 422 patient reviews from WebMD and AskaPatient. Calculated reporting odds ratios (ROR) to identify disproportionate safety signals. Compared oral vs subcutaneous formulations.
Who was studied
FAERS database reports and social media posts about oral and subcutaneous semaglutide
What this study cannot tell us
FAERS data is based on voluntary reporting, which introduces significant biases — adverse events are underreported and reporting rates vary by severity and publicity. Social media data is unverified. ROR signals indicate disproportionate reporting, not causation or incidence rates. Novel signals (pancreatic failure, Dupuytren's) need confirmation in controlled studies.
How to read the evidence
Moderate evidence: large-scale pharmacovigilance analysis using FDA data, but inherent limitations of voluntary reporting systems mean signals require clinical confirmation.
When this study was published
Published in 2024 with FAERS data through mid-2023. Reflects the most comprehensive adverse event comparison of semaglutide formulations to date.
The bigger picture
Semaglutide is one of the most prescribed drugs worldwide, but its rapid adoption means long-term safety data is still emerging. Post-marketing surveillance through databases like FAERS provides early warning signals that clinical trials — with their limited duration and selected populations — may miss. These findings don't prove causation but warrant further investigation.
Questions still open
- Are the novel safety signals (pancreatic failure, Dupuytren's contracture) confirmed in controlled clinical studies?
- Why might oral and subcutaneous semaglutide have different adverse event profiles despite delivering the same active molecule?
- Should patients with pre-existing pancreatic or liver conditions avoid injectable semaglutide specifically?
Common questions
Is oral or injectable semaglutide safer?
What are the most common side effects of semaglutide?
Read the original research
Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.
Frontiers in pharmacology, 15, 1471615
Citation
Zhang, Jing; Wang, Xiaofen; Zhou, Yiting. (2024). Comparative analysis of semaglutide induced adverse reactions: Insights from FAERS database and social media reviews with a focus on oral vs subcutaneous administration.. Frontiers in pharmacology, 15, 1471615. https://doi.org/10.3389/fphar.2024.1471615